SOMAmer reagents are a new class of potential therapeutic molecules
Each SOMAmer modified aptamer that binds to a target protein is equivalent to a high-quality monoclonal antibody to that same protein, although easier and more cost-effective to manufacture reliably. And, like antibodies, select SOMAmer reagents may be therapeutic molecules in their own right. Together with our pharmaceutical company partners, we are validating and developing specific SOMAmer reagents as potential drugs for several different diseases.
If you would like to learn more about potential licensing opportunities, please contact us.